Overview

Ribbon is a blank check company incorporated in the Cayman Islands with the purpose of merging with or acquiring another business. The company went public through an initial public offering (IPO) in January 2025, raising $50 million. Since then, Ribbon has been focused on identifying and evaluating potential acquisition targets, culminating in a proposed business combination with DRC Medicine Inc. announced in June 2025.

Financial Performance

Ribbon has not generated any operating revenue to date, as it has been in the pre-acquisition phase since its inception. The company’s activities have been primarily organizational and related to the IPO and the search for a suitable acquisition target.

For the three months ended June 30, 2026, Ribbon reported a net loss of $19,601, consisting of $338,611 in operating expenses offset by $319,010 in investment income earned on the funds held in the company’s trust account. For the six months ended June 30, 2026, Ribbon reported net income of $233,154, with $416,397 in operating expenses and $649,551 in investment income.

Liquidity and Capital Resources

Ribbon raised $50 million through its IPO in January 2025, with an additional $2.22 million raised from the private placement of units. These funds are being held in a trust account and will be used to fund the company’s initial business combination and related expenses.

As of June 30, 2026, Ribbon had a working capital deficit of $1,797,571 and had used $88,766 in net cash for operating activities. The company may seek additional funding from its sponsor or affiliates, including a $600,000 promissory note issued in March 2026, to meet its working capital needs. However, management has expressed substantial doubt about the company’s ability to continue as a going concern until the completion of the initial business combination or the required liquidation date.

Recent Developments

In June 2025, Ribbon entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc. to acquire DRC Medicine. This proposed transaction is still pending, with Ribbon’s shareholders approving an extension of the deadline to complete the deal from January 2026 to January 2027.

Ribbon has also made several other adjustments to its operations, including:

• Extending the deadline to complete the initial business combination and amending the trust agreement to require monthly extension payments
• Issuing a $600,000 promissory note to Ribbon Investment Company Ltd.
• Depositing additional funds into the trust account to fund the monthly extension payments

Outlook

Ribbon’s ability to complete its initial business combination and continue as a going concern is dependent on its success in acquiring a suitable target. The company faces significant costs and uncertainty in pursuing this goal, and there is no assurance that it will be able to do so within the required timeframe. Ribbon’s financial position and future prospects remain highly uncertain at this stage.